Kathryn Doyle to Speak at CBI’s Mergers and Acquisitions and Strategic Alliances in Life Sciences Conference
CBI, a leader in conferences for the pharmaceutical industry, is hosting interactive discussions on the legal and business nuances of creative deal-making, licensing and collaboration strategies.
In Q1, there were 35 deals completed, representing deal value of $166.3 billion, a value higher than 2014 total deals alone and there’s no sign of a slowdown. Rising equity valuations, historically low interest rates and the demand to use deal-making to add revenue growth and/or business focus all continue to fuel this explosive uptick in deals.
Learn the latest deal-making strategies from a legal and business perspective — from our esteemed faculty of leading life sciences transactions lawyers and business development executives. Our experts get you proficient in the different deal-making options available — life sciences mergers, acquisitions, collaborations and licensing agreements — including various legal implications and how your alliances can create value, while mitigating risk.
Saul Ewing partner, Kathryn Doyle, will speak about “Assessing the Strength of a Target’s Intellectual Property Portfolio and the Impact on Deal-Making.”
The conference will take place October 14th and 15th at The Ritz Carlton in Philadelphia, PA.